Evaxion Highlights Phase 2 EVX-01 Melanoma Results
Copenhagen, Denmark, July 17, 2026 Evaxion A/S announced that it will present three-year clinical efficacy data from its Phase...
Cancer Immunotherapy
Advertisement
GSK Completes Nuvalent Acquisition to Expand Lung Cancer
LONDON, July 16, 2026 GSK plc has officially completed its acquisition of Nuvalent, Inc., marking a major strategic expansion...
Moderna Doses First Patient in mRNA-4200 Cancer Trial
CAMBRIDGE, Mass., July 16, 2026 Moderna, Inc. has announced the first participant has been dosed in its Phase 1...
CancerVax Advances Smart mRNA Immunotherapy
LEHI, Utah, July 14, 2026 CancerVax announced the successful development and in vitro validation of a novel Polyepitope Smart...
Universal Brain Earns FDA 510(k) for Brain Function Technology
SAN FRANCISCO, Calif., July 13, 2026 Universal Brain has achieved a significant regulatory milestone after receiving U.S. Food and...
Advertisements
Leads Biolabs Secures Six ESMO 2026 Research Presentations
NANJING, China, July 13, 2026 Leads Biolabs has strengthened its position in global cancer immunotherapy after announcing that six...
UroGen Announces FDA Clearance of IND for UGN-501 in Bladder Cancer
PRINCETON, N.J., July 8, 2026 UroGen Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared...
Seres Therapeutics Reports Positive Early SER-155 Data
CAMBRIDGE, Mass., July 8, 2026 Seres Therapeutics announced encouraging topline results from an investigator-sponsored clinical trial (IST) evaluating SER-155...
Treos Bio Reports PolyPEPI1018 Immune Remodeling Data
LONDON, Boston & Budapest, July 2, 2026 Treos Bio announced new translational findings from its Phase Ib/II OBERTO-301 clinical...
92Bio Doses First Patient in Phase 1 Trial of NTB-928 for Platinum-Resistant Ovarian Cancer
SAN DIEGO, Calif., July 1, 2026 92Bio, Inc. announced that the first patient has been dosed in its Phase...
Advertisement
